A PYMNTS Company

Utah Reaches Antitrust Settlement With Sandoz Over Generic Drug Pricing

By  |  December 17, 2025

Utah regulators have reached a settlement with global pharmaceutical company Sandoz Inc. in a lawsuit alleging anticompetitive conduct in the generic drug market, marking another step in a multistate effort to address rising prescription drug costs.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Utah Department of Commerce’s Division of Consumer Protection and the Utah Attorney General’s Office announced Tuesday that Sandoz will pay $1.52 million to the state. According to a statement from the attorney general’s office, the payment is tied to allegations that the company participated in unlawful price-fixing involving several generic medications.

    The settlement stems from a broader lawsuit brought by attorneys general across the country, alleging that Sandoz and other drug manufacturers conspired to fix prices between 2009 and 2014. Per a statement released by Utah officials, the state joined the multistate litigation in 2016 and has continued to pursue accountability through the courts.

    Earlier this year, Sandoz also agreed to pay $275 million to resolve related claims brought by U.S. consumers and other plaintiffs nationwide, according to reporting by Reuters in February. Those claims similarly alleged coordination with competitors to inflate generic drug prices.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Utah officials said the agreement may provide financial relief for consumers who were impacted. According to a statement from the attorney general’s office, Utah residents who purchased affected generic drugs during the relevant time period may qualify for compensation under a previously approved consumer settlement.

    Read more: Recovery Firms Accused of Exploiting Class Members in Generic Drug Price-Fixing Case

    Beyond the monetary payment, the settlement imposes behavioral requirements on the company. Utah officials said Sandoz must refrain from price-fixing, bid-rigging, or market allocation for the next five years and must continue operating its existing antitrust compliance program, per a statement outlining the terms of the agreement.

    State leaders framed the resolution as part of a broader effort to make prescription drugs more affordable. “When pharmaceutical companies manipulate the market, it drives up costs for everyday Utahns who need access to affordable medications,” said Utah Attorney General Derek Brown in a statement. “We’re committed to ensuring that Utahns pay fair prices for the prescriptions they depend on.”

    Margaret Busse, executive director of the Utah Department of Commerce, also highlighted the role of the Division of Consumer Protection in pursuing the case. “Utah will never stop pursuing justice for consumers against those who unlawfully inflate the price of potentially lifesaving medication. We hope all affected Utahns will look into this settlement to determine if they can get any closer to being made whole in this price-fixing scheme,” she said.

    Officials emphasized that the agreement with Sandoz does not conclude the state’s broader antitrust case. According to a statement from the attorney general’s office, Utah continues to pursue claims against other defendants named in the ongoing litigation as part of its effort to promote fair competition and protect consumers from inflated drug prices.

    Source: KSL